InvestorsHub Logo
Followers 11
Posts 546
Boards Moderated 0
Alias Born 08/18/2017

Re: ATLnsider post# 590272

Tuesday, 05/02/2023 7:47:13 PM

Tuesday, May 02, 2023 7:47:13 PM

Post# of 704626
Ashkan describes differentiation in the trial as using IL-4 and GM-CSF. Can the maturation agent be replaced like that simply because it’s in a patent?

Still finding this hard to believe.

Would that not be like saying when L is approved it will be for clean room production (as in the trial) and for Flaskworks.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News